Gene editing

CRISPR gene editing
#Cardiovascular disease #Gene editing #Gene therapy #Intellia Therapeutics #Phase III trial

Intellia pauses gene therapy trial due to liver injury

Intellia Therapeutics announced it has temporarily paused its MAGNITUDE and MAGNITUDE-2 Phase III clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN), respectively.  The action follows a report of Grade 4 liver transaminases and increased total bilirubin in a patient who… Read More

#Editor's Choice #News

Gene therapy
#Gene editing #Gene therapy #Genetic diseases #Huntington's disease #uniQure

Trial shows slowing of Huntington’s progression for the first time

A global clinical trial for a new Huntington’s disease gene therapy has posted positive results, including 75% less progression of the disease.  AMT-130 is the first gene therapy to be tested in people with Huntington’s. This is also the first time a drug trial has reported continuing,… Read More

#News #Trending News

#AI #Gene editing

Revvity and Profluent collaborate on gene-editing toolkit

Revvity has announced a collaboration with biotechnology company Profluent to accelerate the development of novel gene-editing therapies.  The collaboration will bring together a range of Profluent’s novel AI-engineered enzymes with Revvity’s established Pin-point base editing platform, creating a therapeutically relevant base editing toolkit.  The new Pin-point configuration will allow for increased… Read More

#Business & Investment #News

#Artificial intelligence (AI) #CRISPR #Gene editing #Genetics / genomics #Large language model (LLM)

Stanford team creates AI gene editing tool ‘CRISPR-GPT’

A team at Standford have created CRISPR-GPT, a large language model (LLM) agent system to automate and enhance CRISPR-based gene-editing design and data analysis.   CRISPR-GPT leverages the reasoning capabilities of LLMs for complex task decomposition, decision-making and interactive human–artificial intelligence (AI) collaboration.  The system incorporates… Read More

#Editor's Choice #News

Gene editing
#Eli Lilly #Gene editing #Gene therapy #Mergers and acquisitions #Verve Therapeutics

Lilly to acquire gene editing specialists Verve Therapeutics

Eli Lilly and Verve Therapeutics have announced a definitive agreement for Lilly to acquire Verve.  Verve is developing a pipeline of gene editing medicines designed to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime.   Verve's lead programme… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Alzheimer's #CNS #Gene editing #Human disease models #Interview #Neurodegenerative disorders #Neurology #Neuropsychiatric disorders #Neuroscience #Precision medicine #PrecisionLife #Stem cells

Podcast: Unlocking neuroscience drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovative uses for biomarkers in drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Advances in neuroscience drug discovery”, “Putting human data at the centre of… Read More

#News

#Alpha-1 antitrypsin deficiency #CAR-T #Gene editing #RNA #Sickle cell disorder (SCD)

Tessera Therapeutics presents new preclinical data

Biotech Tessera Therapeutics has presented updates across its in vivo genetic medicine programmes for Alpha-1 antitrypsin deficiency (AATD), Phenylketonuria (PKU), and Sickle Cell Disease (SCD), as well as advances in in vivo T cell therapies. These data were shared across four oral presentations and three poster presentations at the American Society of Gene and… Read More

#News

#CRISPR #Gene editing #Gene therapy #Rare disease

Personalised CRISPR gene editing therapy treats rare disease

A landmark study from the Children’s Hospital of Philadelphia (CHOP) and Penn Medicine has showcased the power of a customised gene editing therapy to treat a patient with a rare metabolic disease. A child diagnosed with rare genetic disorder severe carbamoyl phosphate synthetase 1 (CPS1) deficiency was… Read More

#Editor's Choice #News

Gastrointestinal tract
#Cell and gene therapy #Cell therapy #CRISPR #Gastrointestinal #Gene editing #Oncology

CRISPR TIL therapy shows early success in GI cancers

Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) cancers.   The results, published in Lancet Oncology, show encouraging signs of safety and potential… Read More

#Cancer Research #Editor's Choice #News

#Adverse event #Cancer research #CAR-T #Cardio #CRISPR #CRISPR-Cas9 #Drug discovery #Gene editing #Imaging #Oncology #Screening

New podcast: Innovation enabled by new drug discovery technologies

This is the latest episode of the free DDW narrated podcast, titled “Innovation enabled by new drug discovery technologies”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “CRISPR breakthroughs: New solutions for common diseases” and “Re-assessing the risks of… Read More

#News

DNA vector
#Gene editing #Gene therapy #iECURE #Phase II trial

Study indicates gene editing could restore OTC enzyme activity

Gene editing company iECURE has shared data from the ongoing OTC-HOPE Phase I/II study of ECUR-506, which suggest partial restoration of functional ornithine transcarbamylase (OTC) enzyme activity in the first patient dosed.  “Long-term restoration of ornithine transcarbamylase activity has the potential to allow infants afflicted with neonatal… Read More

#News #Trending News

Gene editing
#Base editing #Beam Therapeutics #Clinical trial #Gene editing #Gene therapy #mRNA

First clinical genetic correction of a disease-causing mutation reported

Biotechnology company Beam Therapeutics says initial data from its Phase I/II trial establish clinical proof-of-concept for BEAM-302 as a potential treatment for alpha-1 antitrypsin deficiency (AATD) and for in vivo base editing.  Preliminary results from the first three single-ascending dose cohorts demonstrated that BEAM-302 was… Read More

#Editor's Choice #News

Hepatitis B
#Gene editing #Gene therapy #HBV #hepatitis #Phase I trial #Precision BioSciences

Positive early clinical signs for HBV gene editing therapy

Precision BioSciences has announced positive initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ELIMINATE-B trial.   The ELIMINATE-B trial is designed to investigate PBGENE-HBV at multiple ascending dose levels with three dose administrations per dose level… Read More

#Editor's Choice #News

Hepatitis virus
#Gene editing #Genetics / genomics #hepatitis #Interview

Can this gene editing company develop a functional cure for HBV?

DDW Editor Reece Armstrong speaks to Cassie Gorsuch, Vice President, Gene Therapy, at Precision BioSciences about limitations in treating hepatitis B (HBV) and the company’s recent clinical trial application (CTA) approval in Moldova for its lead candidate PBGENE-HBV. RA: What are the limitations of current standard-of-care treatments for HBV?  CG:… Read More

#Exclusive Content

Eye
#Beam Therapeutics #Gene editing #Genetic engineering #Stargardt disease

Base editing technique could treat retinal diseases

Researchers have developed a gene editing therapy that could potentially treat Stargardt disease, the most common form of inherited macular degeneration.   The study, published in Nature Medicine, demonstrates the therapeutic use of a precision gene editing technology called base editing. … Read More

#News #Trending News

CRISPR gene editing
#CRISPR #CRISPR-Cas9 #ETH Zurich #Gene editing #Genetics / genomics

Scientists discover dangerous side-effect of CRISPR technique

Researchers have uncovered that a molecule used to increase the efficiency of CRISPR-Cas9 gene editing destroys parts of the genome.  The team discovered that while AZD 7648 does improve efficiency, it has the unwanted side effect of destroying other areas of the genome. They argue that alternatives… Read More

#Editor's Choice #News